Pacific Bio (PACB) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts PACB Hot Sheet
Join SI Premium – FREE
Pacific Bio (NASDAQ: PACB) reported Q2 EPS of ($0.17), in-line with the analyst estimate of ($0.17). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $23.79 million.
For earnings history and earnings-related data on Pacific Bio (PACB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shopify tanks 19% premarket as Q3 GMV, subscription revenue miss estimates
- InMed Pharmaceuticals Inc. (INM) Misses Q1 EPS by 36c
- IPG Photonics (IPGP) Tops Q3 EPS by 15c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
